Location advantages continue to combine to make Essex a significant centre of life sciences research and innovation. The ‘London-Stansted-Cambridge Corridor’, which has been identified as an emerging growth area for life sciences businesses, has just been placed top of the European “dynamism” league in a report from Savills Investment Management that benchmarks European cities against each other.
A key location at the centre of the corridor is Chesterford Research Park in which Uttlesford District Council has recently purchased a 50% share of to become joint owners alongside Aviva Investors. To celebrate this, and the recent influx of companies to the Park, Cabinet members from Uttlesford District Council and INVEST Essex were given a tour of the facilities of two of Chesterford’s most recent arrivals, Arecor and Evonetix.
Choosing Essex as a location for business expansion
The visit was organised by INVEST Essex, Essex County Council’s Inward Investment delivery partner. INVEST Essex worked with Arecor and Evonetix, as well as specialist Japanese plastics company Enplas, on their choice of location and introduced them to Uttlesford District Council to enable them to take advantage of the Business Development Rate Relief Scheme. This resulted in three companies locating their premises at Chesterford Research Park within nine months.
"We are thrilled to be assisting companies such as Arecor, Evonetix and Enplas find ideal locations from which to do their innovative and ground-breaking work. The opportunities for life science companies in Essex is only going to get better as more and more companies see the value of moving to the dynamic London Stansted Cambridge Corridor. We look forward to assisting the current and future companies with their business expansion in Essex."
Location Services Director
Leading companies choosing Chesterford for research and development
Arecor, a spin out from Unilever in 2007, is developing a portfolio of products to enable improved treatments for diabetes care. Earlier this year the company was awarded £1.05 million towards its development of a ready to use glucagon pen for diabetic patients. The funding will support continued preclinical development of Arecor’s proprietary stable liquid glucagon that will replace glucagon powder and speed up the treatment process for diabetic patients with hypoglycaemia.
Evonetix was founded in late 2015 with the support of Cambridge Consultants Ltd (CCL) and the entrepreneur and co-founder of Amadeus Capital Partners, Hermann Hauser. The company is developing a novel method of manufacturing DNA molecules, using a microchip-based array.
Enplas also develops and mass-produces various life science products. The company specialises in micro-engineered products for life sciences such as ‘lab on a chip’ (LOC) a device that integrates laboratory functions on a single chip of only millimetres to a few square centimetres in size.
“It was a very interesting tour and fascinating to learn more about some of the exciting work happening on the Park. These companies are doing important work and it is encouraging they have chosen Chesterford to continue their operations. The Park is an ideal environment for companies to grow and prosper, and it is a major player in the biotechnology, research and development cluster which is so important for the region.”
Uttlesford District Council
The three companies joined major bioscience players such as AstraZeneca and Domainex who have all chosen Chesterford as the base from which to advance their research and development.
Chesterford Research Park was chosen as the best location for integration into the local medical technologies (MedTech) sector due to its strategic position in the London-Stansted-Cambridge corridor.
See here for more information on Chesterford Research Park.